Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

Learn how common late-life mental illness is, and what new treatments mean for geriatric care.

Rajesh Tampi, MD, previews APA talks on geriatric psychiatry.

Large meta-analysis finds GLP-1 drugs don’t raise depression or suicidality and modestly boost quality of life and eating control in diabetes/obesity.

Learn how to better assess and manage behavioral and psychological symptoms of Alzheimer disease dementia.

Auvelity is now approved for the treatment of Alzheimer disease agitation. Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP, weighs in.

New RCT shows DBT cuts suicidal crises and self-harm in borderline personality disorder more than SSRIs, though benefits fade after treatment.

Research reveals that reducing anticholinergic burden can significantly enhance cognitive function in patients with psychosis, offering new treatment insights.

Explore how placebo effects vary across psychiatric disorders, revealing significant symptom improvements, especially in major depressive disorder and generalized anxiety disorder.

Explore the complexities of insomnia in older adults, its impact on health, and effective management strategies for improved sleep quality.

Discover the most effective components of cognitive behavioral therapy for chronic insomnia, enhancing treatment outcomes and patient care strategies.

Review the September Special Report with articles on geriatric psychiatry, from a variety of experts.

Geriatric psychiatry faces a critical shortage of specialists, impacting the mental health care of the rapidly growing older adult population.

Combining cognitive behavioral therapy with medication enhances ADHD treatment in adults, showing significant benefits within 3 months.

Antidepressant treatment for late-life depression enhances cognitive functions like memory and learning, linking symptom relief to cognitive improvement.

Social media use among older adults shows potential benefits for reducing loneliness and improving psychosocial well-being, though results vary across studies.

In this CME article, learn more about the complexities of neuropsychiatric symptoms in Parkinson disease, including psychosis and cognitive impairment, and effective treatment strategies.

Research reveals that IV haloperidol and ziprasidone are safe for treating delirium in patients that are critically ill, showing minimal impact on QTc intervals.

In this CME article, explore the complexities of Parkinson disease, focusing on neuropsychiatric symptoms, their prevalence, and effective treatment strategies for improved patient care.

New research reveals that discontinuing long-term benzodiazepine therapy may increase risks of mortality and other adverse outcomes, challenging common assumptions.

Ketamine or ECT? A new study reveals which works best for severe depression—depending on the patient and setting.

Recent research demonstrated that xanomeline-trospium is more efficacious than placebo in treating positive and negative psychotic symptoms in adults with schizophrenia.

Clinicians should consider rTMS as an intervention to alleviate OCD symptoms, especially in those who have failed other treatments or those with comorbid depression.

Patients with personality disorders would benefit from therapy regardless of modality, duration, or intensity.

A systematic review and meta-analysis showed moderate-quality evidence supporting lithium’s ability to lower mortality rates.

A new study shows that rTMS has moderate therapeutic effects on OCD severity.

In this CME article, learn more about the efficacy and tolerability of brexpiprazole for the treatment of agitation among individuals with Alzheimer disease dementia.

Evidence indicates that children and adolescents with ADHD have a more than 4-fold increased risk of schizophrenia spectrum and other psychotic disorders in adulthood compared with the general population.

The behavioral and psychological symptoms of dementia contribute significantly to the greater rates morbidity and mortality among those with dementia.

This randomized, placebo-controlled, phase 3 clinical trial showed that a 14-day treatment course of oral zuranolone 50 mg/day in MDD led to significantly greater improvements in depressive symptoms when compared with placebo.